Newly-diagnosed Pediatric T-cell ALL Protocol

Prior treatment

• Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)

Other illness

• Down's syndrome, or major congenital or hereditary disease with organ dysfunction
• Known underlying congenital immunodeficiency or metabolic disease
• Congenital heart disease with cardiac insufficiency.
• Any significant comorbidities or psychiatric disorders that may impact patient safety, compliance, informed consent, study participation, follow-up, or the interpretation of study results. In such cases, all participating sites must report directly to the PI to determine whether the patient meets exclusion criteria.
• Severe malnutrition, active infections, heart failure, or chemotherapy intolerance.

Other

• B-ALL
• AML
• Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.
• ALL evolved from chronic myeloid leukemia (CML).
• Secondary leukemia

• Age older than 1 month to younger than 18 years.
• Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
• Diagnosis of T-ALL by immunophenotyping.